Skip to main content
Premium Trial:

Request an Annual Quote

Genome Therapeutics Posts Reduced Q3 Revenue, Strong R&D Growth, Widened Net Loss

This update serves to correct an error in fact. Third-quarter revenue derived from Genome Therapeutics' GenomeVision division fell by $1.3 million year over year, not $4.2 million as originally reported. GenomeWeb regrets the error.

 

NEW YORK, Nov. 12 - Genome Therapeutics today reported slumping third-quarter revenue atop substantial R&D growth and a ballooning net loss.

 

Total revenue for the period ended Sept. 30 fell to $5 million from $7.4 million during the same time one year ago. Broken down, the contraction reflected revenue slides from Genome Therapeutics two divisions--Biopharmaceuticals and GenomeVision--which respectively drew $1.1 million and $1.3 million less in the third-quarter 2002 over 2001.

 

R&D spending, meantime, swelled to $9.2 million in the third quarter 2002 from $5.2 million in the year-ago period as Genome Therapeutics in-licensed its drug candidate for certain severe bacterial infections.

 

Consequently, third-quarter net loss surged to $10 million, or $.44 per share, from $4.2 million, or $.18 per share, year over year, the company said.

 

Genome Therapeutics said it had roughly $58.4 million in cash, cash equivalents, restricted cash, and investments as of Sept. 30.

 

The company's earnings follow cost-cutting steps the company took in September that cost 34 staffers their jobs. As GenomeWeb reported, employees from early-stage R&D efforts and from administrative support were let go, sparing Genome Therapeutics' later-stage clinical-research and drug-development efforts, the firm said.

 

The move, which is expected to leave the company with 165 full-time staff while saving it about $6 million a year, will not affect any of the revenue-producing early-research partnerships it has with pharma, a Genome Therapeutics official said at the time.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.